Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review

Alexander Yaney 1, Andrew Stevens 2, Paul Monk 3, Douglas Martin 1, Dayssy A. Diaz 1 and Shang-Jui Wang 1*

1 Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, United States, 2 College of Medicine, The Ohio State University, Columbus, OH, United States, 3 Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, United States

Globally, prostate cancer is one of the most common malignancies affecting men. With the advent of advanced molecular imaging, an increasing number of men are found to have oligometastatic disease (OD) either at primary diagnosis or at the time of biochemical failure. No strict definition exists for OD, with historical and ongoing studies utilizing diverse criteria. There is mounting evidence from many different malignancies that patients with OD have improved outcomes compared to their widely metastatic counterparts. As such, treatment intensification of those with OD or oligoprogressive disease has become an area of intense interest and study. This article will review the biology, evidence and controversy behind the treatment of de novo oligometastatic, oligorecurrent and oligoprogressive prostate cancer.

Keywords: prostate cancer, radiotherapy, oligometastatic prostate cancer, oligorecurrent prostate cancer, oligoprogressive castration resistant prostate cancer, ADT (androgen deprivation therapy)

INTRODUCTION

Prostate cancer is the second most common malignancy and sixth most common cause of cancer-related death among men worldwide (1). Due to the advent of screening prostate-specific antigen (PSA), prostate cancer is typically diagnosed early in the disease course, particularly in developed countries. However, PSA screening recommendations made by the USPSTF in 2012 led to a decline in PSA screening, which resulted in an increase in the incidence of high-risk and metastatic disease at diagnosis, particularly in certain racial and ethnic groups (2–4). While outcomes for low- and intermediate-risk prostate cancer are favorable, a significant proportion of men with high-risk disease will experience recurrence and spread of their cancer (5, 6).

Of those diagnosed with metastatic disease at any point in their disease course, a wide spectrum in total metastatic burden exists, from a single lesion to diffuse disease. Traditionally, systemic therapy has been the mainstay of treatment for these patients, with radiotherapy being used for palliation, if warranted (7, 8). However, recently this treatment paradigm is shifting, particularly in the setting of oligometastatic, oligorecurrent and oligoprogressive disease (9–11).

The aim of this mini-review is to present and summarize the concepts of oligometastatic, oligorecurrent and oligoprogressive prostate cancer in addition to the current evidence on the role of radiotherapy in the management of these distinct disease entities. Evidence to include in this
minireview was obtained through search of PubMed for peer-reviewed, original studies on prospective trials and clinicaltrials.gov for ongoing/accruing trials in the three distinct oligometastatic disease settings.

BACKGROUND AND DEFINITIONS

While the exact meaning of clinical oligometastatic disease is controversial, most recent clinical trials and clinical reviews have used ≤3-5 metastatic lesions (12). This disease state can be seen either at the time of initial diagnosis (with synchronous metastases), at which point it is considered de novo oligometastatic disease, or in the recurrent setting (with metachronous metastases), which is considered oligorecurrent disease (ORD) (12). The exact prevalence of oligometastatic prostate cancer is difficult to describe with any degree of certainty due in part to the lack of a standardized definition, different clinical scenarios in which it can arise (de novo or recurrent) and the varying imaging modalities utilized to stage these men (conventional imaging vs. positron emission tomography (PET)-imaging) (10). One study by Larbi et al. utilized whole body MRI to determine the proportion of patients with oligometastatic disease (defined as ≤3 lesions) among 96 men diagnosed with de novo metastatic prostate cancer and found that 28% of patients with castration-naïve prostate cancer and 50% of those with castration-resistant disease met criteria for oligometastatic disease (13). Likewise, a study by Müller et al. sought to determine the prevalence of oligometastatic disease (defined as ≤3 lesions) in 110 men with biochemical recurrence after prostatectomy utilizing prostate-specific membrane antigen (PSMA) PET imaging and reported that 30% of patients could be classified as having oligometastatic disease (14).

What is perhaps more important than the clinical definition of oligometastatic disease is its biologic definition and its accompanying implications. Multiple models for the biology of cancer exist, the oldest being the Halsted theory, which proposes that cancer spreads in an orderly fashion from the primary site to regional lymphatics to distant locations (15). In contrast to this, the Fisher theory proposes that cancer is inherently a systemic disease, even if it is evident only locally (16). It is in the third theory of cancer biology, the spectrum theory, in which the concept of oligometastatic disease lies and its importance is highlighted. In this theory, cancer exists in various degrees of clonal evolution, with varying metastatic potential, which evolves over time. In this theory, the concept of oligometastatic disease represents just one timepoint along the evolution of disease, a point which could represent an intermediate state between localized and widely metastatic disease in which cancer cells have limited metastatic potential and thus may be amenable to cure with total elimination of disease burden (12, 17, 18).

The concept of eradication of oligometastatic lesions as a means of improving cancer-specific outcomes has been studied in several malignancies. For instance, surgical resection of liver metastases in addition to primary disease from colorectal cancer confers cure in one of six patients (19). Similarly, local consolidation of primary and oligometastatic sites in both non-small cell lung cancer (NSCLC) and breast cancer have led to significant improvements in or prolongation of progression-free survival (PFS) and overall survival (OS) (19–24). However, management of men with de novo or recurrent oligometastatic prostate cancer (OPC) is currently controversial, especially in regard to metastases-directed local therapy. This is reflected by the largely ambiguous guidelines provided in the Prostate Cancer NCCN guidelines, stating that SBRT to metastasis can be considered in the setting of 1) limited metastatic disease when ablation is desired (e.g. impending fracture or encroachment on spinal nerves/vertebrae), 2) in oligometastatic progression when PFS is the primary goal, or 3) if there is a symptomatic lesion in or close to a previously treated region (25). Optimal management of men with de novo or recurrent OPC has become more important now than ever due to the advent of advanced molecular imaging, such as PSMA-PET, which has led to an increase in the number of men diagnosed with oligometastatic disease due to its improved sensitivity and specificity over conventional imaging (CI) (26).

On the other hand, oligoprogressive disease is characterized by disease progression in a few sites (again, usually ≤3-5) while on systemic therapy, with the disease biology complicated by selective pressure from systemic treatment. While metastases-directed therapy for both lung and breast cancer in the de novo oligometastatic setting appears to be beneficial, recent phase II data suggests that local therapy to oligoprogressive lesions improves outcomes in NSCLC, but not in breast cancer, underscoring the notion that oligometastatic disease is driven by underlying biology rather than a strict clinical definition (27).

The optimal treatment paradigm for oligoprogressive prostate cancer also remains unclear (12). MDT in oligoprogressive prostate cancer is often utilized to delay a change to next-line systemic therapy, although prospective data is lacking to demonstrate outcome benefits of this clinical practice.

RADIOThERAPY IN DE NOVO OLIGOMETASTATIC DISEASE

While available data to guide the use of radiation (RT) in de novo OPC is sparse, existing studies sought to address the role of 1) treatment to the primary tumor and 2) treatment to both the primary tumor and oligometastatic sites (see Table 1). STAMPEDE Arm H examined the use of radiotherapy to the primary tumor in men with newly diagnosed metastatic prostate cancer. In this study, 2,061 men with metastatic prostate cancer (mPCa) of any metastatic disease burden were randomized to systemic therapy (androgen deprivation therapy (ADT) alone from 01/2013 to 12/2015, with docetaxel allowed in addition to ADT from 12/2015 onward) with or without RT to the prostate to either 36 Gy in 6 fractions given once weekly or 55 Gy in 20 fractions delivered over 4 weeks. While the primary endpoint of OS difference was not significant between the RT and no RT arms, subgroup analysis showed a significant improvement in OS
in men who received prostate RT in the setting of low-volume metastatic disease as per the CHAARTED trial (defined as not having visceral metastases or ≥4 bone metastases with at least one outside of the spine/pelvis; HR 0.68, 95% CI 0.52-0.9; p=0.007), indicating a potential benefit of primary site local therapy in the setting of *de novo* OPC. Subsequently, an exploratory analysis of STAMPEDE Arm H using a more refined definition of metastatic disease burden was performed. In this analysis, patients with non-regional lymph node or ≤3 bone metastases were found to have improved OS (HR 0.62, 95% CI 0.46-0.83 vs. 1.08, 95% CI 0.91-1.28, p=0.003, respectively) and failure-free survival (0.57, 95% CI 0.47-0.70 vs. 0.87, 95% CI 0.76-0.99, p=0.002, respectively) compared to those with ≥4 bone or any visceral metastases (9). Furthermore, of 1939 men with skeletal metastases, the benefit of local therapy continuously decreased with increasing number of lesions (28). Importantly, only 5% of patients in the radiotherapy arm reported a grade 3 (G3) or grade 4 (G4) toxicity and no grade 5 (G5) toxicities were noted, indicating that the potential benefit of local therapy in OPC is not offset by significant toxicity (9, 29). Along with showing clinical benefit, local therapy appears to be cost-effective. Lester-Coll et al. conducted a cost-effectiveness study utilizing data from men with low-burden metastatic disease utilizing STAMPEDE Arm H data and found that the inclusion of prostate-directed radiotherapy in addition to ADT was associated with higher quality-adjusted life years at a lower cost than ADT alone, with a savings of >$30,000 with lifetime follow-up (30).

HORRAD is another phase III study that examined the effect of local treatment to the prostate in the setting of *de novo* OPC. 432 men with previously untreated *de novo* mPCa, PSA>20 ng/mL and unlimited bone metastases were randomized to either ADT alone or ADT with RT to the primary tumor consisting of either 70 Gy in 35 fractions given over 7 weeks or 57.76 Gy in 19

### TABLE 1 | Prospective trials evaluating the role of radiotherapy in (oligo)metastatic prostate cancer.

| Study          | Disease Type       | Metastatic Burden | Study Type | N     | Randomization (if applicable) | Primary Outcome | Result                                                                 | Toxicity                  |
|----------------|--------------------|-------------------|------------|-------|-------------------------------|----------------|----------------------------------------------------------------------|---------------------------|
| STAMPEDE Arm H | *De novo* metastatic disease | Any metastatic burden | Phase III RCT | 2.061 | ADT (+/- docetaxel) vs. ADT (+/- docetaxel) with prostate RT | OS           | OS difference not significant overall (HR 0.92, 95% CI 0.80-1.06). Subgroup analysis showed significant benefit in OS for those with low metastatic burden (HR 0.68, 95% CI 0.52-0.9; p=0.007)* | G3 or G4 in 5% of patients |
| HORRAD         | *De novo* metastatic disease | Any metastatic burden | Phase III RCT | 432   | ADT alone vs. ADT with prostate RT | OS           | OS difference not significant (HR=0.90, 95% CI 0.70-1.14)             | Not reported              |
| SABR-COMET     | ORD                | 1-5 metastases    | Phase II RCT | 99**  | MDT vs. Standard of care for their respective malignancies | OS           | OS improved in MDT arm (5-year OS 42.3% vs. 17.7%, p=0.006)           | G5 in 4.5% of patients    |
| STOMP          | ORD                | ≤ 3 metastases    | Phase II RCT | 62    | MDT vs. Observation           | ADT-free survival | Median ADT-free survival improved in MDT arm (5-year ADT-free survival 34% vs. 8%, p=0.06) | No G2 or higher tox.     |
| ORIOLE         | ORD                | ≤ 3 metastases    | Phase II RCT | 54    | MDT vs. Observation           | Rate of disease progression at 6 months | Disease progression was improved in MDT cohort (Progression at 6 months 19% vs. 61%, p=0.005) | No G3 or higher tox.     |
| Glicksman et al.| ORD                | No limit           | Single-arm Phase II Trial | 37    | PSMA-PET-guided MDT with SBRT or surgery, without ADT | Biochemical response | 60% overall response rate with 22% having complete response | No G2 or higher tox.     |
| Kneebone et al.| ORD                | 1-3 nodal or bone metastases | Single-arm Phase II Trial | 57    | SBRT to metastatic sites without ADT | Biochemical failure** | At median follow up of 16 months, median bDFS was 11 months, with 31.9% bDFS at 15 months | No G3 or higher tox.     |
| Siva et al.    | ORD                | 1-3 nodal or bone metastases | Clinical Trial Feasibility Study | 33    | One fraction of SBRT to each lesion | Feasibility and tolerability | All but one patient completed the prescribed dose to metastatic sites | One patient with G3     |
| Pezzulla et al.| OPD                | ≤ 5 non-visceral, nodal metastases | Post hoc analysis of phase I clinical trials | 38    | SBRT to lesions (in addition to concurrent ADT) | Biochemical response and toxicity | 2-year next line systemic therapy-free survival of 67.7% | One patient with > G1    |

*Defined as not having visceral metastases or ≥4 bone metastases with at least one outside of the spine/pelvis.

**N=16 with prostate cancer.

***PSA level of nadir +0.2ng/mL following MDT.
fractions given three times per week. The primary endpoint, OS, was not significant between the two arms (HR=0.90, 95% CI 0.70-1.14). Moreover, subgroup analysis of patients with fewer than 5 metastases also did not demonstrate a statistically significant difference in OS (HR 0.68, 95% CI 0.42-1.10) (31). While this may cast doubt on the benefit of local therapy in the oligometastatic setting, it is imperative to note that a pooled analysis of the STAMPEDE and HORRAD trials showed a 7% improvement in 3-year survival in men with fewer than 5 bone metastases (32). The role of local therapy in the setting of metastatic disease is further being explored in the prospective trials PEACE-1 and SWOG 1802, although the eligibility for either trial include patients with any number of metastatic lesions, making their relevance in OPC uncertain at this time (33, 34).

The concept of treating both the primary tumor in addition to metastasis-directed therapy (MDT), or total consolidative therapy (TCT), is gaining traction in OPC. Most data regarding TCT comes from small, retrospective studies. For instance, one experience from the University of Rome consisting of 37 previously radiotherapy-naïve patients with ≤5 metastases who underwent TCT showed promising results, with OS and biochemical relapse-free survival (b-RFS) at 5 years of 65.4% and 39.3%, respectively, with no instances of ≥G3 acute or late toxicity reported (35). A separate retrospective study reported by Deantoni et al. included 39 men with bone-only (≤2) metastases showed similarly favorable outcomes with TCT, with 4-year rates of b-RFS and OS of 53.3% and 82.4%, respectively. In this study, no acute ≥G3 toxicities were noted, and no toxicity of any severity was reported for treatment of metastatic sites (36). The only prospective evidence for TCT in OPC comes from a single prospective registry trial that consisted of 12 men with de novo OPC (≤5 metastases) who underwent sequential treatment with neoadjuvant chemotheraphy, radical prostatectomy, MDT +/- adjuvant RT to the prostatic bed/pelvis followed by adjuvant ADT. At 3 years, 67% of men were free from biochemical failure and all remained alive, with no ≥G3 acute toxicities and no late toxicity of any severity reported (37). An ongoing small single-arm phase II trial (NCT03298087) is also evaluating the efficacy of TCT in de novo OPC patients with prostatectomy, MDT to metastatic lesions, and adjuvant radiotherapy with 6-months of ADT, apalutamide and abiraterone, with final results not yet reported (Table 2) (38). Taken together, these studies suggest that TCT for men with de

### Table 2: Ongoing/future trials evaluating radiotherapy/MDT in oligometastatic prostate cancer.

| Study | Disease Type | Metastatic Burden | Study Type | Randomization (if applicable) | Primary Outcome |
|-------|--------------|-------------------|------------|-------------------------------|-----------------|
| STAMPEDE Arm M | De novo OMD | ≤5 lesions | Phase III RCT | SOC (+ prostate RT/surgery) vs. SOC (+ prostate RT/surgery) + MDT | OS |
| NCT03298087 | De novo OMD | ≤5 lesions | Single-arm Phase II RCT | Prostatectomy + MDT + adjuvant RT with 6 months of ADT/apalutamide/abiraterone | PSA <0.05ng/mL 6 months after recovery of testosterone |
| PLATON | De novo OMD and ORD | ≤5 lesions | Phase III RCT | SOC* vs. SOC + MDT | FFS at 6 years |
| NRG-GU011 | ORD | ≤5 lesions | Phase II RCT | MDT + placebo vs. MDT + relugolix | &PFS by conventional imaging |
| DART | ORD | ≤5 lesions | Phase II RCT | MDT vs. MDT + darolutamide | MFS at 2 years by PET |
| RADIOSA | ORD | ≤3 lesions | Phase II RCT | MDT vs. MDT + LHRH agonist/antagonist | PFS |
| ECOG-ACRIN 8191 | Biochemical recurrence | No limit** | Phase III RCT | Salvage RT + ADT/apalutamide vs. Salvage RT + ADT/apalutamide + MDT | PFS, QOL |
| FORCE | OPD | ≤5 lesions | Phase II RCT | SOC vs. SOC + SBRT to all sites of disease | Mean response duration |
| PEACE-1 | De novo metastatic disease | No limit | Phase III RCT | SOC (ADT +/- docetaxol) vs. SOC + abiraterone vs. SOC + prostate RT vs. SOC + abiraterone + prostate RT | OS, rPFS |

*SOC includes ablative therapy (surgery or SBRT) to prostate for patients with untreated prostate primary and low volume metastatic disease. **Conventional imaging negative, no limit on 18F-fluciclovine PET positive lesions.

OMD, oligometastatic disease; RCT, randomized controlled trial; SOC, standard of care; MDT, metastasis-directed therapy; OS, overall survival; ADT, androgen deprivation therapy; PSA, prostate-specific antigen; ORD, oligorecurrent disease; SBRT, stereotactic body radiotherapy; FFS, failure-free survival; rPFS, radiographic progression-free survival; MFS, metastasis-free survival; LHRH, luteinizing hormone-releasing hormone; PFS, progression-free survival; QOL, quality of life; OPD, oligoprogressive disease; RT, radiotherapy.
de novo OPC may be a feasible management strategy with low risk of clinically significant toxicity.

While the previously discussed studies offer promise regarding the potential for TCT in the setting of OPC, phase III trials remain the gold standard to evaluate the benefit of MDT in addition to local therapy to the prostate for men with OPC. One such future trial is STAMPEDE Arm M that will enroll men with de novo OPC who plan to undergo local therapy (surgery or RT) and will be randomized to receiving systemic therapy with or without MDT, with those receiving MDT effectively receiving TCT (Table 2). However, it is imperative to note that de novo OPC in STAMPEDE Arm M is being defined by CI only, rather than by more sensitive molecular imaging such as PSMA-PET, leaving the question of how to optimally manage men with de novo OPC defined by PSMA-PET unanswered (39). The ongoing phase III Canadian PLATON trial (NCT03784755) also defines de novo or recurrent OPC using CI and randomizes these patients to with or without MDT (40). Designing future trials to assess the efficacy of PET-guided MDT in de novo OPC is warranted to complement the results from these CI-defined OPC trials, especially with the recent rapid adoption of PSMA-PET for upfront initial staging.

### Radiotherapy in Oligorecurrent Disease (ORD)

Most evidence for MDT in oligometastatic disease comes from phase II RCTs in the setting of ORD, although the diversity of primary endpoints among studies can make the clinical application of RT unclear (see Table 1). One such trial is the SABR-COMET, in which 99 patients with ORD from various malignancies with 1-5 metastases underwent a 2:1 randomization to MDT with stereotactic radiotherapy vs. SOC for their respective malignancies, with a primary endpoint of OS. It is important to note that only 16 of the 99 patients included in this trial had prostate cancer. At 5 years, OS was 42.3% in the MDT arm compared to only 17.7% who were treated with SOC. While this appears to be an impressive improvement in OS with the addition of MDT, this study is not without criticisms. First, given that this study included multiple histologies, with prostate cancer representing only a small fraction, it is difficult to apply these results to all patients with oligorecurrent prostate cancer. Moreover, there was a skewed proportion of prostate cancer patients between the two arms, with prostate cancer patients comprising 21% of those who received MDT compared to only 6% of those who received SOC. The favorable natural history of prostate cancer may have led to a higher OS rate in the MDT arm. A final criticism of this study is that the rate of G5 toxicity was 4.5% in those treated with MDT, which is exceedingly high and not consistent with the plethora of evidence that supports the safety of MDT, although none of these deaths occurred in patients with prostate cancer. Of note, 2/3 of G5 toxicities occurred in patients undergoing thoracic SBRT, which is uncommon in the setting of mPCa (41, 42).

Many of the concerns regarding SABR-COMET and its relevance to men with prostate ORD can be addressed by having a more homogeneous study population. STOMP is a phase II RCT that randomized 62 men with prostate cancer who had asymptomatic ORD, defined as 3 or fewer metastases on choline-PET, after prior primary curative therapy in a 1:1 fashion to MDT or observation. The primary outcome of this study was ADT-free survival, with indications to start ADT for symptomatic or local progression or development of additional metastases. At a median follow up of 3 years, median ADT-free survival was 13 months in the surveillance cohort compared to 21 months for those who received MDT (HR 0.60, 80% CI 0.40-0.90, p=0.11). Of note, in contrast to the severe toxicities noted in SABR-COMET, no G2-5 toxicities were reported in this study (43). ORIOLE is another phase II RCT that utilized MDT in the oligorecurrent setting. This trial randomized 54 men with hormone-sensitive mPCa with ≤3 metastases based on CI in a 2:1 fashion to MDT with SBRT or observation. The study’s primary outcome was the rate of disease progression at 6 months, which was significantly improved in the MDT cohort compared to the observation group (19% vs. 61%, p=0.005). Again, in contrast to SABR-COMET, no G3 or greater toxicities were reported in this study (44).

Several smaller single-arm prospective studies have also demonstrated the safety and efficacy of MDT in ORD. A study by Glicksman et al. enrolled patients with rising PSA after radical prostatectomy and either adjuvant or salvage RT who had negative CI but positive PSMA-PET findings on restaging scans. Patients were treated with PSMA-PET-guided MDT with SBRT (n=27) or surgery (n=10) without ADT. At a median follow up of 15.9 months, 22% of treated men had an undetectable PSA, with a 60% overall response rate and a median time to PSA progression of 17.7 months, allowing for further delay in ADT administration. No G3 or greater toxicities were noted in patients who received SBRT (45). Similarly, a study by Kneebone et al. treated 57 oligorecurrent patients with 1-3 metastatic nodal or bone sites detected via PSMA-PET with SBRT to the metastatic sites without ADT. The primary endpoint was biochemical failure, defined as PSA level of nadir +0.2 ng/mL following MDT. At a median follow-up of 16 months, the median biochemical disease-free survival (bDFS) was 11 months, with 31.9% bDFS at 15 months. No G3 or greater toxicities were noted in this study (46). A separate feasibility study by Siva et al. treating 33 patients with 1-3 metastases by NaF-PET and CI also showed favorable results with or without ADT, with all but one patient completing the prescribed 20 Gy in 1 fraction dose to sites of metastatic disease. Two-year distant PFS was 39%, and 48% of those treated without ADT remained free from ADT at 2 years. Only one G3 toxicity was reported (47).

The use of MDT in ORD is not only clinically beneficial but can also be a cost-effective treatment strategy. One cost-utility analysis based on the STOMP trial showed that MDT appeared to have an 85.9% probability of being cost-effective in comparison to surveillance with delayed ADT and a 100% probability of cost-effectiveness in comparison to immediate...
ADT (48). A separate study utilizing the SABR-COMET clinical data found that MDT was cost-effective in 97% of all iterations in comparison to standard of care on probabilistic sensitivity analysis. While SABR-COMET was based in Canada, an additional analysis was performed based on United States payer perspective and yielded similar results with a 98% probability of cost-effectiveness (49).

Taken as a whole, these studies evaluating the use of MDT in the setting of oligorecurrent prostate cancer demonstrate that MDT is a cost-effective treatment strategy associated with minimal toxicity and the potential to delay disease progression and the use of ADT/systemic therapy. Furthermore, for a subset of patients, albeit likely small, MDT for ORD may even achieve long-term disease control. However, prospective phase III studies are warranted to further investigate the clinical benefit of MDT in this setting. Currently, several phase II trials are ongoing to evaluate the potential benefit of combining a short-course of hormonal therapy with MDT to improve disease control (Table 2). NRG-GU011 (NCT05053152), D ART (NCT04641078), and RADIOSA (NCT03940235) aim to investigate the addition of relugolix, darolutamide, and LHRH agonists/antagonists, respectively, to MDT (50–52). On the other hand, in the setting of biochemical recurrence after prostatectomy, phase III ECOG-ACRIN 8191 seeks to evaluate the role of MDT in patients with CI-negative but 18F-fluoroclovine PET-positive extra-pelvic metastases at time of PSA progression, which addresses a timely question of whether local therapy of PET-detected metastatic disease (of lower tumor burden compared to CI-detected disease) will alter patient outcomes (Table 2) (53).

RADIOThERAPY IN (OPD) OLIGOPROGRESSIVE DISEASE

With the advent of systemic therapy options that have led to prolonged survival compared to historical standards, even in men with widespread metastatic disease, there has been growing interest in the use of radiotherapy for OPD, with the rationale being that treating sites of oligoprogression may allow patients to remain on the same agent for a longer duration by eradicating tumor clones that have developed resistance to the agent (11). However, no large prospective study exists on the clinical utility of radiotherapy in the setting of OPD, although a prospective trial is currently accruing (Table 2). The main source of prospective data regarding OPD is a pooled analysis of two phase I studies that assessed the use of stereotactic RT in primary, oligorecurrent and oligometastatic cancers. This analysis included men with metastatic castration-resistant prostate cancer (mCR-PCa) with 5 or fewer metastases (without visceral metastases) and progressive nodal metastases. In total, 38 patients were included, all of whom were receiving ADT at time of treatment. Two-year next line systemic therapy-free survival (NEST-FS) was 67.7% and only one patient had a ≥G1 toxicity (G2 dysphagia for supraclavicular field treatment) (54). Beyond this, one must look to retrospective studies for further data. Herein, a subset of these studies will be discussed. One retrospective study by Onal et al. reviewed 54 men with mCR-PCa with 5 or fewer PSMA-PET or bone scan-detected progressive lesions in the lymph nodes or bones treated with SBRT to all lesions while receiving abiraterone or enzalutamide. With a median follow-up of 19.1 months, median prostate cancer-specific survival (PCSS) and PFS were 27.8 months and 12.7 months, respectively. Of note, the number of oligoprogressive lesions requiring treatment and the time between start of abiraterone or enzalutamide and RT treatment were prognostic factors for PCSS on univariate analysis, although the number of lesions treated was only borderline significant on multivariate analysis (p=0.06). Further supporting the use of RT to delay a change in systemic therapy, SBRT to oligoprogressive lesions allowed for continuation of the patients’ current systemic therapies for a median of 8.6 months (11). A second retrospective study by Onal et al. of 67 patients treated with SBRT to 5 or fewer PSMA-positive oligoprogressive lesions showed similarly favorable results, with 2-year OS of 86.9% and only 32.8% of patients progressing to next-line systemic therapy at a median time of 16.4 months from completing SBRT (55).

Likewise, Deek et al. reported outcomes of 68 patients with mCR-PCa who received RT to 1-5 progressive lesions. Following MDT, median time to PSA recurrence, time to next intervention and distant metastasis-free survival were 9.67 months, 15.6 months and 10.8 months, respectively. Median OS had not been reached at median follow-up of 30.9 months. Of note, patients with consolidation of all disease (progressive and stable lesions) were also included in this study, with those receiving TCT having improved outcomes compared to those treated to oligoprogressive lesions alone (56). Additional retrospective studies have shown similar findings with MDT to oligoprogressive sites delaying the need to change systemic therapy, with reported median time to NEST-FS of 15.2 months (57), 16 months (58) and 21.8 months (59), and prolonged distant progression-free survival of 21.6% at 2-years (60).

While additional prospective evidence is needed to further clarify the role of RT in oligoprogressive prostate cancer, these retrospective studies demonstrating a prolongation of NEST-FS and/or PFS suggest that MDT to oligoprogressive sites of disease is a potential treatment strategy that may increase the effective time-window of any given systemic therapy for at least a subset of men with OPD. The phase II FORCE trial seeks to further explore this notion in a different light. Rather than examining NEST-FS or PFS without changing systemic therapy, the primary objective of FORCE trial is to assess the mean duration of response of men with oligometastatic castrate-resistant disease receiving next-line systemic therapy randomized to with or without MDT (61). Certainly, more prospective trials are necessary in the OPD setting to optimize the use of MDT to maximize the utility of systemic therapies available for castrate-resistant disease.

CONCLUSION

While the role of RT in de novo OPC, ORD and OPD remains unclear, clinically meaningful outcomes have been
demonstrated with MDT to OPD and ORD. Larger trials are needed to answer several questions, including which patients will not benefit from this strategy and which patients stand to receive the most benefit, perhaps even cure. With various ongoing studies in this realm currently underway (Table 2), the clinical benefit of MDT in the oligometastatic setting will likely be further clarified soon.

REFERENCES

1. Culp MB, Sorejomotaram I, Esfathioiu JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. *Eur Urol* (2020) 77(1):38–52. doi: 10.1016/j.euro.2019.08.005

2. Taft HE. Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. *Am J Mens Health* (2018) 12(6):1807–23. doi: 10.1177/1557988318798272

3. Tchetter SA, von Landenberg N, Cole AP, Gild P, Choueiri TK, Lipsitz SR, et al. Contemporary National Trends in Prostate Cancer Risk Profile at Diagnosis. *Prostate Cancer Prostatic Dis* (2020) 23(1):81–7. doi: 10.1038/s41391-019-0157-y

4. Kensler KH, Pernar CH, Mahal BA, Nguyen PL, Trinh QD, Kibel AS, et al. Benefits and Risks of Primary Treatments for High-Risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. *Eur Urol* (2020) 77(5):614–27. doi: 10.1016/j.euro.2020.01.033

5. Teo MY, Rathkopf DE, Kantoff P. Treatment of Advanced Prostate Cancer. *Annu Rev Med* (2019) 70:679–99. doi: 10.1146/annurev-med-051517-011947

6. Catton CN, Gospodarowicz MK. Palliative Radiotherapy in Prostate Cancer. *Semin Urol Oncol* (1997) 15(1):65–72.

7. Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial - ScienceDirect. Available at: https://www.sciencedirect.com/science/article/pii/S0140673618324893?via%3Dihub (Accessed 2022 Mar 4).

8. Rao A, Vapilama N, Schaeffer EM, Ryan CJ. Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure? *Am Soc Clin Oncol Educ Book* (2019) 39:309–20. doi: 10.1007/EDBK_239041

9. Onal C, Kose F, Ozyigit G, Aksoy S, Olym M, Muallaoglu S, et al. Stereotactic Body Radiotherapy for Oligoprogressive Lesions in Metastatic Castration-Resistant Prostate Cancer Patients During Abiraterone/Enzalutamide Treatment. *Prostate*. (2021) 81(9):543–52. doi: 10.1002/pros.24132

10. Foster CC, Weichselbaum RR, Pitroda SP. Oligometastatic Prostate Cancer: Reality or Figment of Imagination? *Cancer* (2019) 125(3):340–52. doi: 10.1002/cncr.31860

11. Larbi A, Dallaudière B, Pasoglu V, Padhani A, Michoux N, Vande Berg BC, et al. (WB-MRI) Assessment of Metastatic Spread in Prostate Cancer: Therapeutic Perspectives on Targeted Management of Oligometastatic Disease. *Prostate*. (2016) 76(11):1024–33. doi: 10.1002/pros.23196

12. Müller PJ, Dietlein M, Kobe C, Heidenreich A, Drzezga A. Oligometastatic Disease in Biochemical Recurrence of Prostate Cancer: Prevalence on PSMA PET/CT and Consecutive Metastasis-Directed Therapy - Experience at a Tertiary Referral Center. *Nucl Med Biol* (2022). doi: 10.1055/a-1697-8111

13. Halsted WSI. The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital From June, 1889, to January, 1894. *Ann Surg* (1894) 20(5):497–555. doi: 10.1097/00000658-189407000-00075

AUTHOR CONTRIBUTIONS

AY and S-JW contributed to the conception and outline of the manuscript design. AY and S-JW wrote the manuscript. AS, AY, and S-JW generated the tables. All authors contributed to manuscript revision, read, and approved the submitted version.

14. Müller PJ, Dietlein M, Kobe C, Heidenreich A, Drzezga A. Oligometastatic Prostate Cancer: A Personal Adventure: The David A. Karnofsky Memorial Lecture. *Cancer Res* (1980) 40(11):3863–74.

15. Hellman S. Karnofsky Memorial Lecture. Natural History of Small Breast Cancers. *J Clin Oncol* (1994) 12(10):2229–34. doi: 10.1002/jco.1994.12.10.2229

16. Fisher B. Laboratory and Clinical Research in Breast Cancer-a Personal Adventure: The David A. Karnofsky Memorial Lecture. *Cancer Res* (1980) 40(11):3863–74.

17. Hellman S. Karnofsky Memorial Lecture. Natural History of Small Breast Cancers. *J Clin Oncol* (1994) 12(10):2229–34. doi: 10.1002/jco.1994.12.10.2229

18. Deek MP, van der Eecken K, Phillips R, Parikh NR, Isaacsson Velho P, Lotan TL, et al. The Mutational Landscape of Metastatic Castration-Sensitive Prostate Cancer: The Spectrum Theory Revisited. *Eur Urol* (2021) 80(3):632–40. doi: 10.1016/j.eururo.2020.12.040

19. Tomlinson JS, Jarnagin WR, DeMatteo RP, Yong T, Konrprat P, Gonen M, et al. Actual 10-Year Survival After Resection of Colorectal Liver Metastases Defines Cure. *J Clin Oncol* (2007) 25(29):4575–80. doi: 10.1200/JCO.2007.11.0833

20. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. *J Clin Oncol* (2019) 37(18):1588–65. doi: 10.1002/jco.2019.0209

21. Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, et al. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC. *J Natl Cancer Inst* (2022) djac015. doi: 10.1093/jnci/djaci015

22. Trovo M, Furlan C, Polesi J, Fiorica F, Arcangeli S, Giaj-Levra N, et al. Radical Radiation Therapy for Oligometastatic Breast Cancer: Results of a Prospective Phase II Trial. *Radiother Oncol* (2021) 126(1):177–80. doi: 10.1016/j.radonc.2017.08.032

23. Nicoletti N, Furlan C, Marchetti G. Oligometastatic Breast Cancer Treated With Hypofractionated Stereotactic Radiotherapy: Some Patients Survive Longer Than a Decade. *Radiother Oncol* (2019) 131:45–51. doi: 10.1016/j.radonc.2018.11.022

24. Francesz G, Comito T, Viganò L, Pedicini V, Franceschini D, Clerici E, et al. Liver Metastases-Directed Therapy in the Management of Oligometastatic Breast Cancer. *Clin Breast Cancer*. (2020) 20(6):480–6. doi: 10.1016/jCBC.2020.05.006

25. National Comprehensive Cancer Network. *Prostate Cancer*. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

26. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-Specific Membrane Antigen PET-CT in Patients With High-Risk Prostate Cancer Before Curative-Intent Surgery or Radiotherapy (prePSMA): A Prospective, Randomised, Multicentre Study. *Lancet Lond Eng* (2020) 395(10231):1208–16. doi: 10.1016/S0140-6736(20)30314-7

27. Tsai CJ, Yang JT, Giganó L, Pedicini V, Franceschini D, Clerici E, et al. Oligometastatic Breast Cancer Treated With Hypofractionated Stereotactic Radiotherapy: Some Patients Survive Longer Than a Decade. *Radiother Oncol* (2019) 131:45–51. doi: 10.1016/j.radonc.2018.11.022

28. Ali A, Moyal A, Brawley CW, Cook A, Amos C, et al. Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncol* (2021) 7(4):555–63. doi: 10.1001/jamaoncol.2020.7857

29. Kyrkiopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805
